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Abstract: Obesity affects large numbers of patients with type 1 diabetes (T1D) across their 
lifetime, with rates ranging between 2.8% and 37.1%. Patients with T1D and obesity are 
characterized by the presence of insulin resistance, of high insulin requirements, have 
a greater cardiometabolic risk and an enhanced risk of developing chronic complications 
when compared to normal-weight persons with T1D. Dual treatment of obesity and T1D is 
challenging and no specific guidelines for improving outcomes of both glycemic control and 
weight management have been established for this population. Nevertheless, although evi-
dence is scarce, a comprehensive approach based on a balanced hypocaloric diet, physical 
activity and cognitive behavioral therapy by a multidisciplinary team, expert in both obesity 
and diabetes, remains as the best clinical practice. However, weight loss responses with 
lifestyle changes alone are limited, so in the “roadmap” of the treatment of obesity in T1D, it 
will be helpful to include anti-obesity pharmacotherapy despite at present there is a lack of 
evidence since T1D patients have been excluded from anti-obesity drug clinical trials. In case 
of severe obesity, bariatric surgery has proven to be of benefit in obtaining a substantial and 
long-term weight loss and reduction in cardiovascular risk. The near future looks promising 
with the development of new and more effective anti-obesity treatments and strategies to 
improve insulin resistance and oxidative stress. Advances in precision medicine may help 
individualize and optimize the medical management and care of these patients. This review, 
by gathering current evidence, highlights the need of solid knowledge in all facets of the 
treatment of patients with obesity and T1D that can only be obtained through high quality 
well-designed studies. 
Keywords: obesity, type 1 diabetes, dual diabetes, insulin resistance, metabolic syndrome, 
bariatric surgery
Introduction
The prevalence of overweight and obesity in adults and children is continuously 
increasing worldwide and has doubled in more than 73 countries since 1980.1 Using 
the Global Burden of Disease study data, the estimated prevalence of obesity 
around the world in 2015 was 5.0% in children and 12.0% in adults, with high 
BMI accounting for 4 million deaths mainly due to cardiovascular disease.1 This 
dramatic increase in the prevalence of overweight and obesity affects patients with 
T1D which are especially vulnerable to excess weight. In this regard, increased 
BMI in T1D is associated with a greater cardiometabolic risk and enhanced 
development of chronic complications compared to lean patients with T1D.2 On 
the other hand, insulin resistance leads to high insulin requirements and hinders 
glycemic control and weight management. In the present review, we will 
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summarize existing data on prevalence, trends, links and 
causes of obesity in patients with T1D.
Dual treatment of obesity and T1D is full of barriers 
and challenges as the equilibrium between intensified insu-
lin therapy and optimal weight is difficult. Nowadays, no 
specific evidence-based guidelines for improving both gly-
cemic control and weight management have been estab-
lished for this population. In this paper, we will review the 
outcomes of specific nutritional, exercise and psychologi-
cal strategies used in this clinical situation that may be 
useful to improve their care. For those patients unable to 
achieve a significant and sustained weight loss with life-
style interventions, we will describe the evidence of 
adjunctive pharmacological treatments added to insulin, 
the potential benefits of approved anti-obesity drugs and 
the indications, outcomes and risks of bariatric surgery 
(BS). Also, in the near future new and more potent anti- 
obesity drugs under development promise to facilitate the 
management of these patients. Our review highlights that 
although it is a growing problem, the knowledge in obesity 
approach in T1D is still very scarce, and therefore there is 
an urgent need for high quality designed studies from 
which evidence-based guidelines can be derived.
Epidemiology of Obesity in Type 1 
Diabetes
How Often Does Obesity Appear in Type 
1 Diabetes?
When dealing with a patient with obesity and diabetes, it is 
essential to make a proper classification into T1D or type 2 
diabetes (T2D) as they are heterogeneous diseases with 
variable clinical presentation and disease progression. T1D 
is caused by autoimmune β-cell destruction, which leads to 
an absolute insulin deficiency, and insulin treatment is 
needed from the onset of the disease. On the other hand, 
T2D is due to peripheral insulin resistance and 
a progressive loss of adequate insulin secretion.3
Obesity affects large amounts of patients with T1D 
across their lifetime, with a prevalence that has increased 
during recent decades, and with rates ranging between 
2.8% and 37.1%.4 However, differences appear according 
to the definition of obesity, the age of the examined popu-
lation, and the country. When obesity is defined as a body 
mass index (BMI) ≥95th percentile, its prevalence ranges 
from 5.2% in Israel for the age cohort 5 to 30 years5 to 
13.5% in adolescents (mean age 15.4 years) from the T1D 
Exchange Registry (T1DX) study, with higher prevalence 
in those of black/African American descent (17.9%) and 
Hispanic/Latino descent (15.9%).6 When a more conser-
vative criteria is used (BMI > 97th percentile), data from 
the large multicenter German and Austrian database 
(Diabetes Patienten Verlaufsdokumentation) showed 
a lower prevalence of obesity of as low as 2.8% among 
patients aged <20 years old.7 In the T1DX and the 
Prospective Diabetes Follow-up Registry, the BMI 
z scores in patients aged 2 to 18 years diagnosed with 
T1D for at least 1 year from Germany, Austria and the 
United States were greater than the respective country- 
specific national data.8 However, in the USA population 
aged 3 to 19 years from the SEARCH for Diabetes in 
Youth Study, youths with T1D had a higher prevalence 
of being overweight (22.1% vs 16.1%), but not of obesity 
(12.6%), than non-diabetic youths.9
When obesity is defined by a BMI ≥ 30 kg/m2, its 
prevalence was 8.9% in patients from Sweden aged ≥18 
years old10 which increased to 35.9% in American men 
between 35 and 67 years11 and 37.1% in one cohort of 
newly diagnosed T1D between 30 and 75 years from 
Australia.12
What Has Happened in the Previous 
Decades Regarding the Relationship 
Between Obesity and Type 1 Diabetes?
Overall, obesity rates seem to have stabilized among 
younger people but have increased over time in adults 
with T1D. In Australia, a retrospective study that included 
1975 children aged <16 years at diagnosis of T1D, showed 
that the prevalence of obesity remained steady (34–35%) 
between 1995 and 2009.13 Similarly, a US study that 
examined trends in obesity over 10 years among 507 
youths (aged 8–16 years) with T1D found a consistent 
prevalence rate across time, suggesting a plateau of obe-
sity incidence.14 However, when adults with T1D from the 
Pittsburgh Epidemiology of Diabetes Complications Study 
were evaluated, the prevalence of obesity increased over 
time, from 3.4% at baseline (1986 to 1988) to 22.7% 
during the final reported time point (2004 to 2007).15 
Notably, the rise in obesity’s prevalence was not due to 
aging of the cohort and occurred faster than the increase in 
the general population.15 Similarly, in the Epidemiology of 
Diabetes Interventions and Complications trial, the obesity 
prevalence in T1D increased from 1% at baseline (1983 to 
1989) to 31% at year 12 (2005), a rate change that was 
much higher than observed in the general population.16
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Is Obesity a Risk Factor for Developing 
Diabetes?
It has been suggested that there is a likely association 
between higher birthweight, childhood obesity and higher 
BMI, and subsequent increased risk of childhood-onset 
T1D.17,18 However, it is unclear at what age obesity 
shows the greatest impact nor the underlying mechanism. 
A British study in 168 young people presenting with T1D 
between 1980 and 2002 showed that both pre-onset and 
post-diagnosis BMI were inversely correlated with age at 
onset, suggesting that heavier children developed T1D 
earlier.19 Similarly, a systematic review and meta- 
analysis that included 4 studies that measured BMI prior 
to the diagnosis of T1D, supported the temporal associa-
tion between exposure to obesity and the development of 
T1D.17,20–23 Although the studies varied in the definition 
of obesity, the age at measurement and in sample size, 
with odds ratios (OR) that ranged from 1.73 to 3.77, the 
metanalysis obtained a pooled OR of 2.03 (95% CI 1.46– 
2.80). On the other hand, the reversed trend in the inci-
dence of childhood T1D in Sweden, starting in 2000, has 
been partially attributed to changes in non-genetic risk 
factors such as the good control of childhood obesity.24 
Finally, in 91 children with clinical onset of type-1 dia-
betes at 4–15 years of age, there was increased weight 
(BMI) gain in the first year of life compared with their 125 
healthy siblings.25 Remarkably, this early growth was 
associated at diagnosis with the presence of autoantibodies 
toward the IA-2 and the tyrosine phosphatase pancreatic- 
cell-like protein, but not with antibodies to glutamic acid 
decarboxylase. Similarly, in the Finnish population, the 
risk of type 1 diabetes onset increased 1.19-fold per 
a 1 kg/m2 rise in the infancy maximum BMI.26
As the combined prevalence of overweight and obesity 
in the childhood population has accelerated in many devel-
oping and developed countries, effective prevention and 
intervention programs should be a priority of national 
policy agendas to avoid the continuing increase of T1D 
in childhood for decades to come.27
Mechanisms Underlying the 
Relation Between Obesity and Type 
1 Diabetes
Among several possible mechanisms highlighted to 
explain the association between obesity and subsequent 
onset of T1D, there appears the classical “accelerator 
hypothesis”.28 In this theory, increased body weight 
boosts the demand for peripheral insulin, imposing more 
stress on β cells and rendering them more antigenic and 
more vulnerable to autoimmune attack. At the same time, 
the ectopic lipid deposition in islets acts as an additional 
trigger of β cell apoptosis and the subsequent onset of 
T1D. Thus, a link between beta cell lipotoxicity and islet 
inflammation related to cytokine toxicity associated with 
obesity has been shown in experimental models.29 Insulin 
resistance in T1D may also implicate the transient receptor 
potential vanilloid-1 (TRPV1+) sensory neurons to pro-
mote the local islet inflammation.30 In fact, TRPV1 may 
contribute to obesity and T2D, where sensory innervation 
of fat may play an analogous role to sensory neurons in 
pancreatic β cells. In addition, adipose tissue is character-
ized by the production of adipokines which stimulate the 
generation of reactive oxygen species and pro- 
inflammatory molecules, collaborating in the development 
of a dysfunctional antioxidant system and insulin- 
resistance.31 In this context, the increased oxidative stress 
that is associated with obesity might make the achieve-
ment of correct metabolic control in patients with T1D 
difficult.
The gut microbiome is altered in obesity and should be 
considered as an important environmental modulator of 
the susceptibility to diabetes in subjects with obesity.32 
In fact, both animal and human studies have demonstrated 
a link between gut microbiota and β cell autoimmunity.33 
However, the underlying mechanisms of how the gut 
microbiota interacts with host immunity, induce antigen- 
specific pathogenic T cells, and modulate β cell autoim-
munity in the initiation of T1D are not yet fully elucidated.
Given that a genetic component is well known to exist 
in T1D, genomics offers an opportunity to discover new 
targets for this disease. In this way, the transcription 
factor 7 like-2 (TCF7L2) loci on chromosome 10, that 
has often been related with T2D in genome-wide associa-
tion studies (GWAS), has also been associated with both 
latent autoimmune diabetes in adults and various presen-
tations of T1D.34 However, this genetic overlap between 
T1D and T2D is still controversial, as Field et al failed to 
find any evidence for association between TCF7L2 and 
type 1 diabetes in 6199 white UK type 1 diabetic subjects 
and 7596 geographically matched white control 
subjects.35 On the other hand, in 830 newly diagnosed 
autoimmune T1D, TCF7L2 variants were associated with 
single autoantibodies at diagnosis, higher C-peptides, and 
lower glucose levels during an oral glucose tolerance 
test.36
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Obesity, Type 1 Diabetes Mellitus, 
and Diabetes Complications
Some studies have assessed the impact of obesity in the 
development of chronic complications in patients with 
T1D, suggesting that individuals with obesity are at an 
increased risk for macrovascular and some microvascular 
complications, such as retinopathy.2,4 Excess weight gain 
in patients with T1D is associated with the development of 
central adiposity, insulin resistance, inflammation and dys-
lipidemia; all of which are key elements of the metabolic 
syndrome and T2D and are established risk factors for 
cardiovascular disease (CVD).37,38 In patients with T1D 
and obesity, the coexistence of these clinical characteris-
tics of T2D, such as insulin resistance and cardiometabolic 
complications, has been referred to as “double 
diabetes”.39,40 (see Figure 1). Regarding this, when the 
components of the metabolic syndrome were evaluated in 
326 individuals with T1D aged between 5 and 34 years, 
the prevalence of low levels of high-density lipoprotein- 
cholesterol was three times higher and hypertension was 
four times higher among obese individuals compared with 
normal-weight individuals.5 In a similar way, the preva-
lence of the metabolic syndrome increased from 4.9% 
among patients with normal weight to 35.3% among 
obese patients.5 Moreover, in an observational study in 
adults with T1D, obesity was associated with the presence 
and progression of coronary artery calcium, a marker of 
subclinical atherosclerosis.41 Similarly, data from the 
Figure 1 In patients with type 1 diabetes adipose tissue deposits produce adipokines and inflammatory cytokines that induce insulin-resistance contributing to the 
development of cardiometabolic complications. The coexistence of these clinical characteristics of type 2 diabetes in patients with type 1 diabetes has been referred to as 
double diabetes.
https://doi.org/10.2147/DMSO.S223618                                                                                                                                                                                                                               
DovePress                                                                                             
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021:14 2810
Vilarrasa et al                                                                                                                                                        Dovepress















































































DCCT showed that in those patients with T1D with the 
most excessive weight gain, there were increases in both 
cardiometabolic risk factors (lipids, blood pressure) and 
more extensive atherosclerosis.37,38 In addition, after year 
14, the cardiovascular events in the intensive insulin ther-
apy group with the most weight gain were significantly 
higher than the minimal weight gain group (P = 0.024; 
unadjusted hazard ratio 1.99; 95% CI, 1.12 to 3.63), with 
the event rate becoming indistinguishable from the con-
ventional group.37,41
Data from 20,985 adults with T1D included in the 
Swedish National Diabetes Registry showed that obesity 
was significantly associated with an increased risk for 
a heart failure hospitalization, with an adjusted Hazard 
Ratio (HR) of 1.55 and 2.90 for BMI 30–34.9 kg/m2 and 
(95% CI, 1.20 to 1.99) and BMI ≥ 35 kg/m2, 
respectively.10 In a prospective study of 501 Australian 
adults with T1D, obesity defined as a BMI > 30 kg/m2 was 
the main risk factor for cardiovascular disease and retino-
pathy, although with a similar HbA1c and disease duration 
compared to non-obese patients.42 In the same study, obe-
sity was also associated with albuminuria in women. 
Similarly, in a cross-sectional study with 176 adults with 
T1D, BMI appeared to be significantly correlated with 
retinopathy only in those without previous nephropathy.43
Patients with T1D and obesity therefore receive more 
drugs than their normal-weight counterparts in order to 
treat the associated cardiometabolic risk factors. This can 
lead to polypharmacy which is a problematic issue as it 
exposes patients to adverse drug reactions, drug-drug or 
drug–disease interactions and is associated with 
morbidity.44
Causes of Increasing Prevalence of 
Obesity in Type 1 DM
Exogenous insulin use and intensive insulin treatment has 
been considered a key factor promoting weight gain in 
patients with T1D.2 Since the Diabetes Control and 
Complications Trial (DCCT), multiple daily injections or 
insulin pump therapy coupled with frequent blood glucose 
monitoring has become the standard of care of T1D.45 
Despite the beneficial outcomes in the DCCT, adults 
receiving intensive insulin therapy gained an average of 
5 kg more than those receiving conventional therapy.46 
However, studies that have followed cohorts of patients 
with T1D in the long term have observed that despite 
doubling the use of intensive insulin therapy after DCCT, 
z-BMI and prevalence of overweight and obesity remained 
stable during a 10-year interval, similar to the general 
pediatric population. These findings go against intensive 
insulin therapy being the main reason for the rising pre-
valence of obesity in patients with T1D.14
It is the availability of high-energy density diets and 
increased portion size, along with a sedentary lifestyle 
which are the main drivers of obesity development 
worldwide.47,48 The trigger therefore of the increasing 
prevalence of obesity in T1D is the obesogenic environ-
ment. Nevertheless, obesity is a complex multifactorial 
chronic disease; besides unhealthy habits, other exogenous 
factors such as the presence of altered eating behavior, 
eating disorders, short sleep duration, chronic stress and 
other psychosocial factors are implicated in its etiology. 
Moreover, current scientific knowledge has shown that 
other non-modifiable endogenous biological factors such 
as gut hormone profile, genetic predisposition, epigenetics 
or intestinal microbiota may also play a role in obesity 
development.49 Different causes of obesity in T1D are 
illustrated in Figure 2.
Regarding biological factors, gastrointestinal hormones 
including ghrelin, cholecystokinin, gastric inhibitory pep-
tide (GIP), glucagon-like peptide-1 (GLP-1), oxyntomodu-
lin, amylin, insulin, leptin, pancreatic peptide and 
pancreatic polypeptide Y (PPY) among others, are key 
regulators in food intake. However, in T1D, the secretion 
of insulin, amylin (which favors delaying gastric emptying 
and inhibits intake) and glucagon are markedly 
dysregulated.50 Apart from the expected loss of secretion 
of amylin and insulin by β cells, α cells are also dysfunc-
tional resulting in a deficient secretion of glucagon in 
Figure 2 Illustration of the main modifiable and endogenous biological factors 
implicated in obesity etiology.
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hypoglycemia and lack of glucagon suppression in the 
postprandial state.51 All this inherent hormonal disbalance 
can potentially contribute to alterations in food intake, thus 
promoting weight gain.
From what has been explained previously, when treat-
ing a patient with obesity and T1D we have to take into 
account the coexistence of two chronic diseases in which 
all the above aspects are interrelated and should be care-
fully addressed.52
Treatment of Obesity in T1D: 
Challenges and Opportunities
The pillars of obesity treatment include a healthy eating 
plan, scheduled physical activity, and behavioral inter-
ventions that should be adapted in case of T1D. 
Structured lifestyle intervention programs have shown 
to be more effective in weight loss than a standard course 
of action in patients with obesity.49 Although evidence is 
scarcer, these structured programs have proven equally 
beneficial when T1D coexists.53 These programs should 
be executed by a multidisciplinary team that includes 
endocrinologists, dietitians/nutritionists, nurses, educa-
tors, physical activity professionals as well as clinical 
psychologists.54 The participation of a diabetes educator 
and a close follow-up by an expert team in diabetes is 
mandatory to adjust carbohydrate intake and to carefully 
titrate insulin dose to prevent hypoglycemia. Indeed, one 
of the main barriers to diet interventions in T1D is the 
occurrence of hypoglycemia and its compensatory 
overeating.55
The administration of short-acting insulin immediately 
after meals or within 20 minutes from the start of the meal 
can be useful in some cases to avoid low glucose values.53 
On the other hand, it is important to assess changes in 
insulin type to those with a more favorable profile in terms 
of weight. Multiple trials have shown that patients with 
diabetes who used insulin detemir as the basal component 
of intensive insulin therapy, maintained weight neutrality 
or even had small weight reductions over 1 year in com-
parison to NPH insulin.56 In a recent meta-analysis includ-
ing patients with T1D and T2D, those receiving insulin 
detemir gained less body weight than those given degludec 
or Glar-100.57 Another systematic review concluded there 
was less weight gain with basal insulin analogues detemir 
and Glar-300 compared to Glar-100 and degludec but with 
a low quality of evidence.58 Therefore, in the case of 
obesity and T1D, switching long-acting insulin to either 
detemir or Glar-300 could be somewhat useful to prevent 
weight gain.
The incorporation of the new technology of continuous 
subcutaneous insulin infusion (CSII) in T1D treatment has 
shown no clinical benefit over multiple daily injections, in 
terms of weight outcomes in newly diagnosed children and 
in young patients with T1D, either during the first year of 
insulinization59 or over a 10-year follow-up.60
Diet
For the management of obesity in T1D lifestyle changes 
are essential, which must necessarily begin with a dietary 
modification towards a healthy eating pattern. A high 
intensity face-to-face dietary intervention program (with 
more than 14 sessions in 6 months) in the context of 
a comprehensive lifestyle intervention is the most effective 
strategy, obtaining average weight losses of 5–10%.53 
A variety of diets can lead to weight loss in overweight 
or obese adults with and without T2D (the Mediterranean- 
diet, low-carbohydrate, vegetarian or plant-based)54,61,62 
but to date, there is inadequate research in T1D to support 
one over another.63 Taking into account that the macronu-
trient composition of a diet has less impact on weight loss 
than the adherence to it, the proposed diet plan must be 
adapted to the clinical characteristics and preferences of 
each patient, and must be planned to facilitate long-term 
adherence. The presence of a dietitian in the multidisci-
plinary team is therefore essential.61
The main component of any dietary intervention in 
obesity, independent of the presence of diabetes, is redu-
cing total caloric intake. An energy reduction in the diet of 
500–1000 kcal per day or 25–30% of the daily caloric 
intake can lead to a weight loss of 0.5 and 1 kg/week, 
equivalent to more than 5% weight loss in an average 
period of 6 months. The reduction of the size of the 
consumed portions and/or the energy density of the diet 
are effective strategies to reduce weight in patients with 
obesity. Focus should be made in T1D in encouraging 
consumption of carbohydrates with low glycemic index 
and high fiber content from vegetables, legumes, fruits, 
and whole grain and avoid refined carbohydrates, added 
sugars and highly processed foods.61–63.
In our environment, the hypocaloric Mediterranean 
diet is the one that best represents this balanced and 
healthy approach that is desired for T1D. The 
Mediterranean diet is characterized by a high content of 
vegetables, fruits, legumes, complex starches and food 
rich in omega-3 fatty acid (fatty fish), omega-6 fatty acid 
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(nuts) and monounsaturated fatty acids (olive oil) and 
promotes low intakes of saturated, trans fatty acids and 
added sugars.64 Moreover, it is associated with a reduction 
in the risk of numerous diseases including cardiovascular 
disease, cancer, type 2 diabetes and neurodegenerative 
diseases.65 Even though hypothetically optimal, there is 
little evidence of Mediterranean diet intervention in T1D. 
In a trial that randomized patients with T1D and metabolic 
syndrome to a 6-month non-calorie restricted 
Mediterranean diet versus a low-fat diet, the effects on 
waist circumference, anthropometric and metabolic out-
comes were similarly favorable with both dietetic 
approaches.66
Current ADA guidelines suggest a flexible approach to 
carbohydrate intake matched with intensive insulin therapy 
because there is no ideal macronutrient composition for 
meal plans.63 However, the evidence of low carbohydrate 
(<130g carbohydrate/day) and ketogenic diets (<55g carbo-
hydrate/day) in T1D deserves special attention. Although it 
is very popular to lose weight in populations with obesity 
and T2D, there is limited evidence of their use in T1D as 
some concerns have been raised mainly regarding the risks 
of hypoglycemia and DKA.67 In this respect, a low carbo-
hydrate diet (LCD) can impair the effect of glucagon in the 
presence of hypoglycemia due to a reduction in hepatic 
glycogen stores. In a study performed on individuals with 
insulin pump–treated T1D, an LCD (<50 g/day) attenuated 
the glycemic response to a subcutaneous glucagon bolus 
compared to a high carbohydrate diet.68
Only a handful of studies, limited by small sample sizes 
and mostly non-RCT, have been published comparing the 
effects of LCD versus higher carbohydrate diets.68–72 
A systematic review based on them concluded that due to 
their heterogeneity it was unclear which diet was superior 
regarding HbA1c improvement, total daily insulin, inci-
dence of hypoglycemia, or BMI.73
Recently, other popular forms of diet plans for weight 
loss are intermittent fasting, understood as the severe 
restriction of intake >60% for 2–3 days a week or alternate 
days, or as a limitation of the intake period to 8–10 hours 
a day or less during most days (time-restricted feeding). In 
review studies and meta-analysis of the few trials carried 
out to date, it has not been possible to verify a significantly 
greater weight loss with these diets compared to conven-
tional low-calorie diets.74,75 Additionally, their effective-
ness and safety in people with T1D have not yet been 
conclusively proven and would therefore clearly require 
adequate training and an adjustment in medication in order 
to avoid hypoglycemia.
From previously revised data we can conclude that 
further studies centered on nutrition-based interventions in 
patients with T1D and obesity are needed. Nevertheless, our 
recommended dietetic approach to lose weight in T1D would 
be a hypocaloric diet based on the Mediterranean diet pattern, 
with 40–50% of the energy coming from carbohydrates with 
low glycemic index and high fiber content (>25–30 g/1000 
kcal), 15–25% from proteins (or 1.2 g/kg ideal body weight), 
and 30–35% from fat (ensuring a high content in monounsa-
turated fats and low in trans and saturated fats).
Physical Activity
The benefits of physical activity on cardiovascular and psy-
chological health are multiple and its promotion is pivotal in 
obesity and T1D management.76 However, patients with 
T1D engage in less physical activity than those without 
diabetes and have a tendency to live a sedentary lifestyle 
that promotes obesity development.77 The practice of physi-
cal activity in isolation as a treatment for obesity has 
a modest effect on weight loss. However, when associated 
with a hypocaloric diet, exercise has been shown to decrease 
fat mass and visceral adiposity, decrease the loss of lean body 
mass, and increase insulin sensitivity. In addition, maintain-
ing physical exercise has been shown to be useful in reducing 
the risk of weight regain.62
The goal for children and adolescents with T1D accord-
ing to ADA recommendations is 60 min of moderate to 
vigorous intensity aerobic activity daily (walking, jogging, 
dancing, pedaling, etc.), with vigorous muscle-strengthening 
and bone-strengthening activities at least 3 days per week.63 
For adults, it is recommended 150 min or more of moderate 
to vigorous intensity aerobic activity per week, spread over at 
least 3 days/week and 2–3 sessions/week of resistance exer-
cise. Shorter durations (minimum 75 min/week) of vigorous 
intensity or interval training may be sufficient for younger 
and more physically fit individuals. The same recommenda-
tions are given for people with obesity.62
The prescription of physical exercise must be individua-
lized and the participation of physical activity professionals 
should be considered for a better adaptation to the charac-
teristics and functional capacity of the patient, with the aim 
of improving adherence. The main barrier to do exercise in 
T1D is the fear of severe hypoglycemia78 that may occur 
during or up to 24 h after exercise due to increased insulin 
sensitivity and delayed replenishment of liver and muscle 
glycogen following exercise. On the other hand, an 
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excessive and/or frequent intake of carbohydrates is not 
advisable in people with obesity because it promotes weight 
gain. Therefore, it is important to be educated on strategies 
to reduce hypoglycemia that can take place during, after and 
overnight following exercise. After exercise, the decrease of 
the long-acting insulin doses by ~20–30%, and 50% of 
bolus (or in case of insulin pumps the reduction of basal 
rate by ~10–50% and 25–75% of bolus or even its suspen-
sion for 1–2 h during exercise), may lower the risk of 
hypoglycemia.79 Along with frequent blood glucose mon-
itoring, accessible rapid-acting carbohydrates before, dur-
ing, and after exercise is advisable. For low-to-moderate 
intensity aerobic activities (30–60 min), and if the patient is 
fasting, the recommendation is 10–15 g of carbohydrate and 
after insulin boluses it can reach 0.5–1.0 g of carbohydrates/ 
kg per hour of exercise.63,80
The use of new technologies such as accelerometers, 
smart-watches, and mobile phone applications can contri-
bute to assess and improve the adherence of patients to 
exercise programs.81
Psychological and Behavioral Therapy
Patients with overweight or obesity are vulnerable to 
stigma and discrimination in the workplace, at school, in 
healthcare settings and in society in general leading to 
negative psychological consequences. Health care provi-
ders should avoid stigmatization and weight bias and 
employ a motivational interview with the patient.82
Psychosocial disturbances in obesity and in T1D are 
frequent and they should be identified and treated 
appropriately.83,84 Some are characteristics of diabetes 
such as fear of hypoglycemia and diabetes distress, and 
others are shared by both diseases such as anxiety, depres-
sion, lack of support, low self-esteem and the distress of 
coping with a chronic disease. Eating disorders are also 
frequent in both entities, with estimated prevalence of 7% 
in patients with T1D85 and reaching 16–50% in cases of 
obesity alone according to different studies.86,87 In patients 
with T1D suffering from eating disorders, insulin omission 
is frequent and is associated with a worse metabolic con-
trol, risk of ketoacidosis events and higher rates of dia-
betes complications.88 On clinical suspicion raised by 
a poor glycemic control and recurrence of hypoglycemic 
episodes, several questionnaires can be useful to identify 
eating disorders in T1D such as the Diabetes Eating 
Problem Survey, Eating Disorder Inventory-3, and modi-
fied SCOFF.89,90 In a preliminary study, initiation of pump 
therapy improved disordered eating behaviors probably 
due to greater flexibility in eating patterns and increased 
regulation of hunger and satiety. However, evidence is still 
scarce and further studies are needed to evaluate the 
impact of CSII insulin pumps on eating problems.91
Derived from the above knowledge, psychological 
assessment and behavioral therapy should be incorporated 
into the routine clinical management of obesity in T1D and 
involve clear and reasonable goal setting, self-monitoring of 
food intake and exercise, an approach to problem solving, 
development of skills for managing difficulties, stimulus 
control, stress reduction, education and social support. 
These behavioral interventions have proven to be beneficial 
in the context of a structured weight intervention program.53
Pharmacological Treatment of Obesity in 
T1D
Those patients who have insufficient weight loss with diet 
and exercise are candidates for drug treatment. Current 
guidelines indicate that pharmacological obesity treatment 
can be used in patients with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/ 
m2 in the presence of complications, as an addition to life-
style changes.49,54,62 Anti-obesity medications approved for 
long-term use by both the EMA (European Medicines 
Agency) and FDA (U.S Food and Drug Administration) are 
Orlistat, Naltrexone-Bupropion and Liraglutide 3.0 mg. The 
Phentermine–Topiramate combination is only FDA 
approved.49,54,62 These treatments have shown that along 
with weight loss there is an improvement in insulin resistance 
and metabolic control in T2D (Table 1) but no data are 
available on their effects on diabetic complications. 
Although these drugs are not contraindicated in T1D, data 
about their use in these patients are nonexistent as they have 
been excluded from the main trials. Despite these limitations, 
it seems reasonable to assume that obese people with T1D 
may benefit from these drugs in real life. Not including T1D 
in pharmacological obesity management clinical trials intro-
duces a bias that leads to a further increase in a discrimination 
due to the obesity of these patients. Table 1 shows the main 
results of these studies in patients with T2D as well as in their 
adverse events and contraindications.
Anti-Obesity Medications
Orlistat 
Orlistat is a reversible inhibitor of lipases. At the recom-
mended therapeutic dose of 120 mg three times a day, 
orlistat inhibits dietary fat absorption by approxi-
mately 30%. In a meta-analysis of 14 studies, orlistat 
reduced weight 2.9% more than placebo.92
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Bupropion is an inhibitor of the reuptake of dopamine 
and norepinephrine and is involved in the regulation of 
appetite (anorectic action) and in the hedonic reward 
circuits. Naltrexone is a µ-opioid inhibitor. In the COR 
(Contrave Obesity Research) studies,93–96 Naltrexone- 
Bupropion sustained-release (SR) at a dose of 32/ 
360 mg reduced weight 4.5% more than placebo 
(Table 1).
Phentermine-Topiramate 
Phentermine has been used for the treatment of obesity 
since 1955, and together with the antiepileptic topiramate, 
this drug combination exerts an anorexigenic action by 
acting on the GABA and glutamate receptors. In the dif-
ferent randomized double-blind studies (EQUIP, 
CONQUER and SEQUEL),97–100 the percentages of total 
weight loss have been, on average: low doses −5.1%, 
medium dose −7.1% and high doses −10.9% (Table 1).






Weight Loss ≥5% Weight 
Loss
Dropouts Side Effects Contraindications
Drug Placebo Drug Placebo






















eating disorders, chronic 
opioid use, concurrent 
use with monoamine 
oxidase inhibitors within 
14 days
COR-193 1 1742 −6.1% −1.3% 48.0% 16.0% 50%
COR-294 1 1496 −6.4% −1.2% 50.5% 17.1% 46%
COR-BMOD95 1 793 −9.3% −5.1% 66.4% 42.5% 48%











concurrent use with 
monoamine oxidase 
inhibitors within 14 days
CONQUER97 1 2487
4(7.5/46 mg) 498 −7.8% −1.2% 62% 21% 30.9%
(15/92 mg) 995 -9.8% -1.2% 70% 21% 36.0%
SEQUEL99 2 676
(7.5/46 mg) 227 -9.3% -1.8% 75.2% 30% 17.6%





1 1026 10.9% -1.6% 66.7% 17.3% 41.2%
Plus CONQUER 1 451 -9.6% -2.6% 65% 24% 19.7%
Liraglutide 






Personal or family history 
of medullary thyroid 
carcinoma or multiple 




1 3731 −8.0% −2.0% 63.2% 27.1% 18%
3 2254 -6.1% -1.9% 49.6% 23.7% 47.4%
Maintenance 
diabetes104
1 422 -6.2% -0.2% 50.5% 21.2% 25%
1 846 -6.0% -2.0% 69.2% 27.2% 26.7%
Notes: Subjects with diabetes were included in specific clinical trials (COR-DIABETES, SCALE Diabetes). For phentermine-topiramate, sub-studies were used that included 
patients with T2D, such as OB-202/DM-230 and a sample from the CONQUER study. 
Abbreviations: COR, Contrave Obesity Research; BMOD, behaviour modification; SCALE, Satiety and Clinical Adiposity — Liraglutide Evidence.
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Liraglutide 3.0 mg 
Liraglutide is an analog of the incretin GLP-1 (Glucagon 
Like Peptide-1) and is well known for its efficacy and 
safety in the treatment of T2D at doses of 1.2–1.8 mg/ 
day. However, the higher dose of 3.0 mg/day is used for 
obesity treatment.
Among the four pivotal SCALE studies (Satiety and 
Clinical Adiposity – Liraglutide Evidence),101–104 the 
study concerning obesity with/without prediabetes, which 
included 3731 patients, showed a total weight loss after 56 
weeks of treatment of −8% compared to −2.6% with 
placebo. A lower decrease was observed in the SCALE- 
diabetes study of −6.0%. Liraglutide’s safety and efficacy 
have been verified for the treatment of adolescents with 
obesity105 (pending approval by regulatory agencies) and 
it is the anti-obesity drug of choice according to some 
societies.62
Other GLP1 Agonists (Semaglutide, Dulaglutide) 
These are long-acting GLP1 analogs approved for use in 
T2D to improve glycemic control which also exert an 
additional action on body weight. In a head-to-head 
study, weekly administered semaglutide 1 mg achieved 
a weight reduction of −6.5 kg compared to 3.0 kg with 
dulaglutide 1.5 mg.106 However, neither treatment was 
intended to treat obesity.
We have preliminary data that show that obese patients 
with T2D treated with high-dose Semaglutide 2.4 mg can 
achieve a reduction of approximately –9·6% and −15% of 
starting weight in patients with and without diabetes, 
respectively.107,108 Of note, one-third of participants in 
this last study achieved 20% of weight loss similar to 
that obtained with sleeve gastrectomy (SG). The develop-
ment of new drugs in the future for weight and glycemic 
control will be based on the combination of drugs like 
tirzepatide (dulaglutide plus a GIP analog), and combina-
tions of GLP1, GIP, Glucagon coagonists/triagonists, com-
binations of Semaglutide and Pramlintide analog 
(Cagrilintide) and the YY peptide agonists.109
The authors believe that for those patients unable to 
achieve a significant and sustained weight loss with life-
style interventions, the addition of approved anti-obesity 
drugs and the use of novel molecules derived from gastro-
intestinal peptides in the near future, will be very useful 
for weight management in T1D patients, as some approach 
bariatric surgery (BS) results. As a growing problem 
worldwide, T1D with obesity should be included in weight 
loss clinical trials.
Oral Glucose-Lowering Drugs as Adjuncts to Insulin 
Treatment in T1D
A number of oral glucose-lowering drugs used in T2D 
treatment have been explored as adjuncts to insulin treat-
ment in T1D in the search of improving metabolic control 
and body weight. Results of the most relevant trials are 
listed in Table 2.
Metformin 
Metformin is the first-line treatment for T2D. It decreases 
hepatic glucose production, increases insulin sensitivity 
and decreases glucose absorption.110 Some clinical trials 
with limited number of participants with T1D have eval-
uated the effects of metformin added to insulin compared 
to placebo and have demonstrated a decrease with respect 
to placebo in insulin dose (−5.7 to −8.8 UI/d) and in 
weight (−1.74 to −3.8 kg), but no effect on HbA1c.111,112 
The REMOVAL trial randomized 428 patients with T1D 
to metformin or placebo and measured the progression of 
common carotid artery intima-media-thickness (cIMT) as 
a marker of atherosclerosis.115 Body weight was reduced 
(−1.17 kg, 95% CI 1.66 to −0.9) but there was no reduc-
tion in HbA1c, insulin requirements, progression of mean 
cIMT and no increase in hypoglycemia compared to 
placebo.
Dipeptidyl Peptidase IV Inhibitors (DPP-IV Inhibitors) 
The DPP-IV inhibitors enhance levels of endogenous glu-
cagon-like peptide 1 (GLP1) by blocking its metabolism 
by the enzyme DPP-IV. This increase of GLP1 levels, 
leads to a decrease in glucagon and an increase in insulin 
secretion. T1D patients experience a paradoxical increase 
in glucagon, which correlates with postprandial glucose 
levels.114 Sitagliptin has been evaluated and compared to 
placebo in a limited number of studies in patients with 
T1D,115,116 none observing significant effects on weight.
Glucagon Like Peptide 1 Analogs (GLP1a) 
Of the six available GLP1a only two have been evaluated 
in patients with T1D: Exenatide and Liraglutide.
Exenatide: There are few studies evaluating exenatide 
in patients with T1D, all methodologically heterogeneous 
and with a limited number of patients. The studies demon-
strate a decrease in insulin requirements,117–119 but only 
a small number of them show a significant decrease in 
HbA1c117,118 and in weight loss.117,119
Liraglutide: The Lira-1 trial showed no differences in 
HbA1c, but there were significant differences in weight 
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loss (−6.8 kg) and in insulin dose (5.8 UI of bolus/day) in 
the group of patients with T1D treated with liraglutide 
1.8 mg/d with respect to the placebo group. In the liraglu-
tide group, the perceived frequency of hypoglycemia was 
lower and the most frequent adverse events were gastro-
intestinal effects.120
The two trials with the largest number of patients at 
present (ADJUNCT ONE and ADJUNT TWO) have 
reported similar results with respect to a significant weight 
loss (from −4.1 to −5.1 kg) and a reduction in insulin dose 
in the liraglutide group, but also a decrease in HbA1c (from 
0.2% to 0.35%).121,122 The gastrointestinal disorders, 
Table 2 Studies Analysing the Effects of Oral Glucose-Lowering Drugs as Adjuncts to Insulin Treatment in T1D
n Duration 
(Weeks)




Change in Insulin 
Dose
Biguanides
REMOVAL113 Metformin 1000 mg 428 156 −0.13** −1.17** −0.05 IU/kg/d
GLP1a
Lira-1120 Liraglutide 1.8 mg 100 24 −0.2 −6.80* −0.1 IU/kg/d
ADJUNCT ONE121 Liraglutide 1.8 mg 1398 52 −0.2 ** −4.90 ** −5%* (∆BL)
Liraglutide 1.2 mg −0.15* −3.55** −2% (∆BL)
Liraglutide 0.6 mg −0.09* −2.19** +4% (∆BL)
ADJUNCT TWO122 Liraglutide 1.8 mg 853 26 −0.35 ** −5.10** Ratio 0.90**
Liraglutide 1.2 mg −0.23** −4.00** Ratio 0.93**
Liraglutide 0.6 mg −0.24** −2.50** Ratio 0.95**
iSGLT2
DEPICT-1124 Dapagliflozin 10 mg 833 52 −0.36** (∆BL) −3.90** NR
Dapagliflozin 5 mg −0.33** (∆BL) −2.56** NR
DEPICT-2125 Dapagliflozin 10 mg 815 24 −0.42** −3.74%† −16.71%
Dapagliflozin 5 mg −0.37** −3.21%† −11.19%
EASE-1126 Empagliflozin 25 mg 75 4 −0.53* −1.90** −0.07 IU/kg/d*
Empagliflozin 10 mg −0.38** −1.80** −0.09 IU/kg/d *
Empagliflozin 2.5 mg −0.49** −1.50** −0.08 IU/kg/d *
EASE-2127 Empagliflozin 25 mg 730 52 −0.45*** −3.60*** −12.9%***
Empagliflozin 10 mg −0.39*** −3.20*** −12.0%***
EASE-3127 Empagliflozin 25 mg 977 26 −0.52*** −3.40*** −12.6%***
Empagliflozin 10 mg −0.45*** −3.00*** −9.5%***
Empagliflozin 2.5 mg −0.28*** −1.80*** −6.4%***
InTandem1128 Sotagliflozin 400 mg 793 52 −0.31** −4.34** −12.64%**
Sotagliflozin 200 mg −0.25** −3.14** −8.02**
InTandem1129 Sotagliflozin 400 mg 782 52 −0.32%* −2.18** −8.17%**
Sotagliflozin 200 mg −0.21%* −1.98** −6.26%*
InTandem1130 Sotagliflozin 400 mg 1402 24 −0.46** −2.98** −5.3 UI/d **
Amylin mimetics
Whitehouse et al133 Pramlintide 30µg or 60µg 480 52 −0.39** NR +2.3%* (∆BL)
Edelman et al134 Pramlintide 30µg or 60µg 296 29 −0.19 −1.3***(∆BL) −12% (∆BL)
Ratner et al135 Pramlintide 60µg or 90µg 651 52 −0.29** NR NR
Notes: †Mean percent change. *p<0.05. **p<0.001. ***p<0.0001. 
Abbreviations: ∆BL, change from baseline; NR, not reported.
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symptomatic hypoglycemia and hyperglycemia with keto-
sis, were more frequent in the liraglutide groups.
Sodium-Glucose Cotransporter Inhibitors 
SGLT2 is located in the renal proximal tubule and favors 
glucose reabsorption and SGLT1 promotes glucose 
absorption in the small intestine. Inhibition of these trans-
porters by SGLT2 and SGLT1 inhibitors leads to 
a decrease in glucose reabsorption in the kidney and the 
small intestine, respectively. Moreover, patients with dia-
betes mellitus present an overexpression of SGLT2.123 
SGLT2 inhibitors and dual (SGLT2 and SGLT1) inhibitors 
have been evaluated in patients with T1D.
Dapagliflozin: The DEPICT-1 and DEPICT-2 trials 
randomized to receive dapagliflozin 5 mg, dapagliflozin 
10 mg or placebo.124,125 In both trials, patients in the 
groups of dapagliflozin presented a significant decrease in 
HbA1c compared to placebo (from −0.33% to −0.37% with 
dapagliflozin 5 mg and from −0.36% to −0.42% with 
dapagliflozin 10 mg), in insulin dose and in body weight 
(the mean percentage change vs placebo ranged from 
−2.95% to −4.54%). There were no differences in the 
rates of hypoglycemia, but incidence of DKA was higher 
in the treatment groups (2.6% to 4% with dapagliflozin 
5 mg, 2.2% to 3.4% with dapagliflozin 10 mg and 0% to 
1.9% with placebo).
Empagliflozin: The EASE-1 trial126 randomized 
patients to receive empagliflozin 10 mg, empagliflozin 
25 mg and placebo and the EASE-2 and EASE-3 
trials127 randomized patients to empagliflozin 2.5 mg, 
10 mg, 25 mg or placebo. All trials showed a significant 
decrease in HbA1c with all doses of empagliflozin vs 
placebo (from −0.28% to −0.53). Patients in the treatment 
groups also experienced a higher reduction in weight 
(from −1.5 kg to −3.6 kg) and in insulin dose. While in 
the EASE-1 there were no differences in the rate of DKA, 
in the EASE-2 and 3127 trials there were higher rates of 
DKA in the groups of patients with the higher doses of 
empagliflozin (10 mg and 25 mg): 0.8% with empagliflo-
zin 5 mg, 4.3% with empagliflozin 10 mg, 3.3% with 
empagliflozin 25 mg and 1.2% with placebo.
Sotagliflozin: The program inTandem has evaluated the 
efficacy and safety of the dual blockade of SGLT1 and 
SGLT2 by sotagliflozin in T1D.128–130 The three trials 
showed a reduction in HbA1c in the groups of patients 
treated with sotagliflozin (from −0.21% to −0.46%), in 
weight (from −1.98 to −4.34 kg) and in insulin dose. The 
frequency of documented hypoglycemia was lower and 
gastrointestinal events and DKA were more frequent in 
patients treated with sotagliflozin. With respect to DKA, 
3.4% of patients with sotagliflozin 200 mg presented 
DKA, 4.2% with sotagliflozin 400 mg and 0.4% with 
placebo.
Amylin Mimetics 
Pramlintide: Pramlintide is a hormone co-secreted with 
insulin in the postprandial period by β cells in response 
to nutrient stimuli. It modulates glucose absorption, delays 
gastric emptying and suppresses glucagon secretion.131 It 
is deficient in patients with T1D.132 Pramlintide is an 
amylin analogue, administered subcutaneously in addition 
to prandial insulin, approved in the USA for the clinical 
use in T1D and T2D. Pramlintide has been evaluated 
adjunct to intensive insulin therapy in T1D and trials 
have shown significant reductions in HbA1c (from 
−0.19% to −0.39% compared to placebo), in weight and 
in insulin doses.133–135 Hypoglycemia and gastrointestinal 
adverse events were more frequent in patients treated with 
Pramlintide.
Of all these evaluated treatments, in addition to pram-
lintide, which has been approved in the USA for T1D 
since 2005, dapagliflozin 5 mg was approved in Europe 
in 2019 for the use in patients with T1D and BMI ≥ 27 kg/ 
m2 when insulin alone does not provide an adequate gly-
cemic control despite optimal insulin treatment.
Natural Product Supplementation
Numerous plants, their extracts and isolated components 
are under investigation for their possible beneficial effects 
on body weight. Phytochemicals are plant organic com-
pounds without nutritional effect but with bioactivity, such 
as carotenoids, polyphenols, flavonoids, alkaloids, tannins, 
steroids, etc., with a large number of phytoconstituents 
such as genistein, capsaicin, catechins, ephedrine or caf-
feine. They are potential sources of new drugs due to their 
biological activity on metabolic pathways involved in the 
regulation of intake and energy balance. In human studies, 
the effect of most of them on body weight is supported by 
low-quality evidence and only some (green tea, white 
kidney bean, caffeine, bitter orange, diacylglycerol, resver-
atrol, grapefruit, chromium) have moderate-quality evi-
dence. However, none is capable of inducing a clinically 
relevant weight loss, with the most effective ones (green 
tea) leading to a 2 kg reduction.136,137 Therefore, for the 
time being, these natural products lack adequate clinical 
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investigations and scientific validation to be recommended 
for obesity therapy.
Bariatric Surgery in T1D with Severe 
Obesity
In patients with T1D and BMI above or equal to 35 kg/m2 
with associated comorbidities or BMI above or equal to 
40 kg/m2, BS can be a treatment option as supported by 
IFSO since 2016.138 However, contrary to firm benefits of 
BS in T2D, little is known of its outcomes and risks in 
populations with T1D.139 Therefore, ADA guidelines state 
that larger and longer studies will be required in order to 
establish the role of metabolic surgery in such patients.61
Pathophysiology
Patients with T1D have a reduced endogenous insulin 
secretion, but body weight loss can decrease insulin resis-
tance in hepatic and peripheral tissues and may improve 
hepatic insulin sensitivity leading to a reduction in insulin 
requirements. A role of gastrointestinal hormones in meta-
bolic improvement has also been suggested in animal 
studies.140 In this regard, a preliminary study in which 
one woman with T1D who underwent RYGB reported an 
increase in the incretin hormones GLP-1, PYY, and GIP 
after a mixed meal test.141 However, other authors were 
not able to correlate GLP-1 nor glucagon concentrations to 
changes in glycemic control and insulin requirements.142
Outcomes of BS in Patients with T1D
The results of obesity surgery in patients with T1D have 
only been described until recently in case reports and 
small series,141–163 most with a short follow-up that have 
given place to several systematic reviews.164–168 The main 
results are summarized in Table 3. Overall, they have 
shown a significant reduction in body weight and weight- 
adjusted insulin requirements and an improvement in other 
cardiovascular risk factors (mainly hypertension, dyslipi-
demia and obstructive sleep apnea). However, only modest 
and transient benefits on glycemic control have been 
found, mainly occurring within the first year after bariatric 
surgery (see Table 3). Our group published the results of 
a cohort of 32 patients with T1D undergoing BS with 
a mean follow up of 4.6 years and observed that HbA1c 
was reduced 0.6% during the first year, but in the long 
term, it returned to baseline values.163 Nonetheless, 
a sustained reduction of 51% in total daily insulin dose, 
and a decrease in about 50% of patients with hypertension, 
dyslipidemia and obstructive sleep apnea was observed.
Safety of BS in Patients with T1D
Besides the improvement of insulin sensitivity after 
weight loss that requires an appropriate reduction in 
exogenous insulin dose, the change in glucose kinetics 
and nutrient intake and absorption may favor hypogly-
cemic events. Regarding this, food intolerance and 
vomiting after bariatric surgery and the mismatch 
between insulin peak after subcutaneous administration, 
and the higher and earlier postprandial glucose excursion 
caused by the rapid delivery of carbohydrates to the 
jejunum promotes hypoglycemia. Thus, this risk would 
be expected to be greater after mixed and malabsorptive 
techniques.169 However, it is still unknown if the type of 
surgical technique has a real impact on hypoglycemic 
events and which one would be the appropriate choice in 
this context. In our retrospective non-randomized series, 
9.3% of patients had a serious hypoglycemic event, but 
their frequency did not differ between those surgeries 
bypassing the duodenum (Roux-en-Y gastric bypass 
(RYGB) and duodenal switch) and with restrictive ones 
(SG).163 Recently, Höskuldsdóttir et al have published 
data from a register-based nationwide Swedish cohort 
including 387 individuals with T1D who had undergone 
RYGB that were compared to 387 age/BMI/sex and 
diabetes duration matched control patients.170 In this 
large bariatric population, there was a numeric but not 
statistically significant difference in hypoglycemic 
events leading to coma (HR 1.57; P = 0.205).
DKA is a life-threatening complication that ranges 
from 6.2 up to 25% in a series of patients with T1D 
undergoing BS.163,171 In the nationwide Swedish cohort, 
a higher risk for serious hyperglycemic events (HR 1.99) 
was found after RYGB surgery compared to controls.170 
Poor peri-operative glycemic control along with omission 
or non-compliance with prescribed insulin doses was asso-
ciated with DKA.
Of note, in the Swedish study a significantly increased 
risk for alcohol and substance abuse was found after 
surgery (HR 3.71), as has also been reported in other 
bariatric series.172
Effects of BS on Diabetic Complications
In preliminary case reports, anecdotical microalbuminuria 
regression to normoalbuminuria153,163 and inconsistent 
results regarding retinopathy have been described.153 In the 
Swedish cohort study, no difference was found regarding the 
risk of kidney disease or leg amputation after RYGB com-
pared to controls.170 A lower risk for cardiovascular disease 
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(hazard ratio [HR] 0.43) and cardiovascular death (HR 0.15) 
was observed in the RYGB group. The differences were most 
marked with regards to stroke (HR 0.18) and heart failure 
(HR 0.32).
In summary, bariatric surgery in T1D patients with 
severe obesity has proved efficient in reducing weight 
and insulin dose and in improving associated 
comorbidities, with recent studies showing a significant 
reduction in cardiovascular disease and mortality. These 
benefits outweigh the adverse events observed, such as an 
increased risk of hypoglycemia and DKA. Nevertheless, 
a close monitoring of these patients by a multidisciplinary 
team is fundamental to provide a tailored, modifiable 
insulin regimen during all phases of management along 
Table 3 Studies Analyzing the Effects of Bariatric Surgery in Patients with T1D













Czupryniak et al144 2010 3 RYGB (n=3) 6.3 years 8.7 0.23 ↓3 BP, dyslipidemia
Mendez et al145 2010 3 RYGB (n=3) 1year 16.5 0.20 ↑0.07
Garcia-Caballero et al 2013157 5 SAGB (n=5) 19m 7 47 UI/d ↓1.6 BP, dyslipidemia
Raab et al 2013148 6 RYGB (n= 2); SG (n=1) 
BPD (n=3)
1 year 13.8 0.57 ↓1.2
Chuang et al 2013147 2 RYGB (n=1); SG (n=1) 20m 18.1 ↑0.05 ↑1.95 BP, dyslipidemia
Fuertes-Zamorano et al 
2013146
2 SADI-S (n=2) 4.5 years 23.0 0.26 ↓0.85 Dyslipidemia
Reyes Garcia et al, 2013158 1 RYGB (n=1) 10 m 14.6 88UI ↓1.3
Blanco et al 2014142 7 RYGB (n=7) 2 years 12.1 ↑0.01 ↓0.1 NS –
Brethauer et al 2014150 10 RYGB (n=7); SG (n=1), 
GB (n=2)
3years 11.1 0.34 ↓1.1 BP, dyslipidemia
Tang et al 2014151 6 RYGB (n=1), SG (n=2), 
GB (n=3)
16 m 11.4 NR ↑0.1 NS –
Lanno et al 2014152 22 RYGB (n=16); SG (n=6) 37 m 8.7 0.3 ↓0.2 NS –
Middelbeek et al 2015153 10 RYGB (10) 5years 9.7 0.05 ↑1.7 Increase in HDL
Maraka et al 2015154 10 RYGB (n=9), SG (n=1) 2 years 13.1 NR ↓0.4 NS Dyslipidemia
Robert et al 2015155 10 BPD (n=7), SG (n=3) 4.5years 16.5 0.7 ↓0.4 NS BP, dyslipidemia
Rottenstreich et al 2015160 13 RYGB (n=) SG (n=10) 2years 9.8 0.19 ↓0.8 NS BP
Vilarrasa et al 2017163 32 RYGB (n=11); SG (n=15), 
DS (n=6)
4.6 years 9.0 0.3 ↑0.2NS BP, dyslipidemia, 
OSA
Faucher et al 2016161 13 RYGB (n=6); SG (7) 1year 11.5 0.33 ↓0.7
Moreno-Fdez et al 2016159 6 RYGB (n=3), SG (n=3) 4.5 years 14.2 0.10 ↓0.6 NS Triglycerides
Al Sabah et al 2017162 10 SG (n=10) 4 years 10.5 0.46 ↓0.3 NS
Landau et al 2019156 26 RYGB (n=10); SG (n=5); 
GB (n=8)
3.5 years 9.3 NR ↑0.04 NS BP, increase HDL
Hoskuldsdóttir et al 2020170 387 RYGB (n=387) 9 years 12 NR ↓0.8 CV disease and 
CV mortality
Abbreviations: BP, blood pressure; OSA, obstructive sleep apnea; CV, cardiovascular; RYGB, Roux- en-Y gastric bypass; SAGB, single anastomosis gastric bypass; SG, 
sleeve gastrectomy; GB, gastric banding; SADI-S, single anastomosis duodeno-ileal bypass with sleeve gastrectomy; DS, duodenal switch.
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with diabetes care and education. New diabetes technolo-
gies such as real-time monitorization may be especially 
helpful in this situation.
Endoscopic procedures
Endoscopic procedures are emerging as obesity treatment 
options but no studies have been published so far in T1D. 
These procedures are minimally invasive, most are rever-
sible, safer and less costly compared to surgical treatment. 
However, they are characterized by the transience of their 
effects and the lack of long-term studies, so that for the 
time being their recommendation as primary treatments of 
obesity is not well established.54,62
Future Perspectives
Non-traditional therapies for patients with T1D and obe-
sity need to be evaluated in the near future.173 In this way, 
pegylated fibroblast growth factor-21 appears as a novel 
metabolic regulator with the potential to become 
a powerful therapy to treat diabetes mellitus.174 
Similarly, adiponectin ameliorates non-alcoholic fatty 
liver disease in streptozotocin-induced T1D.175 Finally, it 
still needs to be established whether immunotherapy may 
find a place in the prevention of progression to overt T1D 
and improve clinical outcomes in established diabetes in 
patients with obesity.176 On the other hand, there is an area 
of research in the development of strategies based on 
reducing oxidative stress in patients with T1D and obesity 
with some evidence coming from supplementation with 
probiotic/symbiotic and a low dietary intake of advanced 
glycation end products.177,178
An extensive pipeline of obesity medications is cur-
rently in Phase II and III development in adults, suggesting 
that more effective treatments will be available in the 
coming years. Some examples are the future combinations 
of drugs such as GLP1 agonists with GIP, Glucagon, or 
oxynomodulin (dual agonists or triagonists), the combina-
tion of Semaglutide with an amylin analog 
(Cagrilintide)179 or the novel Bimagrumab which is 
a monoclonal antibody that binds to the type II activin 
receptor that regulates skeletal muscle growth, but also 
decreases adipose tissue improving insulin resistance.180
Undoubtedly, the big step ahead in the treatment of 
T1D and obesity will be provided by advances in precision 
medicine. Regarding this, the integration of major techno-
logical advances achieved in recent years (including high- 
resolution omic assays, wearable devices that monitor 
behavior and exposure, and digital imaging technologies) 
integrated with genetic information will help individualize 
the efficacy of specific dietary approaches and select med-
ication and surgical techniques for each patient.181 The 
introduction of this tailored treatment will definitively 
enhance the outcomes.
Conclusions
The coexistence of obesity and T1D is a growing problem 
and poses a challenge for effective glycemic and weight 
management. All patients should be offered a lifestyle 
intervention by a multidisciplinary team including 
a balanced hypocaloric diet, physical activity and cogni-
tive behavioral therapy. In the “roadmap” of the treatment 
of obesity in T1D, it will be helpful to include approved 
anti-obesity pharmacotherapy, and in case of morbid obe-
sity, bariatric surgery stands out as an effective procedure 
to reduce weight and comorbid conditions. In the near 
future, the development of new and more effective anti- 
obesity treatments, coupled with strategies to improve 
insulin resistance and oxidative stress and advances in 
precision medicine, will provide very useful tools to 
improve both the weight and metabolic management of 
these patients.
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